Research Summary

Dr. Katsuto Shinohara specializes in urologic cancers, in particular prostate cancer. He has special interests in innovative biopsy techniques and image-guided minimally invasive treatments for prostate cancer, as well as in applying ultrasound techniques in the diagnosis, management and treatment of all urologic cancers.

Shinohara earned his medical degree from Yokohama City University School of Medicine in Yokohama, Japan. He completed a residency in general surgery at Mitsui Memorial Hospital in Tokyo, Japan, and a residency in urology at Kitasato University Hospital in Sagamihara, Japan. He then completed a fellowship in urologic oncology at Baylor College of Medicine in Houston, Texas.

Shinohara is a member of numerous professional societies, including the Japanese Urological Association, Japan Society of Ultrasonics in Medicine, American Institute of Ultrasound in Medicine, American Urological Association and Engineering & Urology Society. He has lectured widely on urologic cancer, and his work has been published in numerous medical and scientific journals.

Education

Yokohama City University, Yokohama City, Japan, Premed
Yokohama City University, Yokohama City, Japan, M.D., Medicine

Selected Publications

  1. Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ, Focal Therapy Society. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 Jul 05.  View on PubMed
  2. Chang K, Greenberg SA, Cowan JE, Parker R, Shee K, Washington SL, Nguyen HG, Shinohara K, Carroll PR, Cooperberg MR. Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging. J Urol. 2023 Aug; 210(2):281-289.  View on PubMed
  3. Shee K, Cowan JE, Balakrishnan A, Escobar D, Chang K, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. Eur Urol. 2023 07; 84(1):9-12.  View on PubMed
  4. Chen HY, Bok RA, Cooperberg MR, Nguyen HG, Shinohara K, Westphalen AC, Wang ZJ, Ohliger MA, Gebrezgiabhier D, Carvajal L, Gordon JW, Larson PEZ, Aggarwal R, Kurhanewicz J, Vigneron DB. Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized <sup>13</sup> C pyruvate metabolic imaging: A technical development study. Magn Reson Med. 2022 12; 88(6):2609-2620.  View on PubMed
  5. Baskin A, Charondo LB, Balakrishnan A, Cowan JE, Cooperberg MR, Carroll PR, Nguyen H, Shinohara K. Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease. Urol Oncol. 2022 10; 40(10):451.e15-451.e20.  View on PubMed
  6. Balakrishnan AS, Nguyen HG, Shinohara K, Carroll PR, Odisho AY. Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy. Urol Oncol. 2022 09; 40(9):407.e1-407.e7.  View on PubMed
  7. Velarde N, Westphalen AC, Nguyen HG, Neuhaus J, Shinohara K, Simko JP, Larson PE, Magudia K. US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy. Abdom Radiol (NY). 2022 03; 47(3):1133-1141.  View on PubMed
  8. Chappidi MR, Bell A, Cowan JE, Greenberg SA, Lonergan PE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2022 05; 207(5):1001-1009.  View on PubMed
  9. Wu SY, Wong AC, Shinohara K, Roach M, Cunha JAM, Valdes G, Hsu IC. Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation. Pract Radiat Oncol. 2021 Nov-Dec; 11(6):515-526.  View on PubMed
  10. Chu CE, Cowan JE, Lonergan PE, Washington SL, Fasulo V, de la Calle CM, Shinohara K, Westphalen AC, Carroll PR. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2022 10; 5(5):537-543.  View on PubMed
  11. Hsu IC, Rodgers JP, Shinohara K, Purdy J, Michalski J, Roach M, Vigneault E, Ivker RA, Pryzant RM, Kuettel M, Taussky D, Gustafson GS, Raben A, Sandler HM. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys. 2021 07 01; 110(3):700-707.  View on PubMed
  12. Fasulo V, Cowan JE, Maggi M, Washington SL, Nguyen HG, Shinohara K, Lazzeri M, Casale P, Carroll PR. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. Eur Urol Oncol. 2022 02; 5(1):61-69.  View on PubMed
  13. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Reply by Authors. J Urol. 2020 12; 204(6):1221.  View on PubMed
  14. de la Calle CM, Fasulo V, Cowan JE, Lonergan PE, Maggi M, Gadzinski AJ, Yeung RA, Saita A, Cooperberg MR, Shinohara K, Carroll PR, Nguyen HG. Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. J Urol. 2021 02; 205(2):452-460.  View on PubMed
  15. Herlemann A, Overland MR, Washington SL, Cowan JE, Westphalen AC, Carroll PR, Nguyen HG, Shinohara K, Cooperberg MR. How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound? Eur Urol Focus. 2021 Nov; 7(6):1268-1273.  View on PubMed
  16. Chu CE, Lonergan PE, Washington SL, Cowan JE, Shinohara K, Westphalen AC, Carroll PR, Cooperberg MR. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. Eur Urol. 2020 10; 78(4):515-517.  View on PubMed
  17. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 12; 204(6):1216-1221.  View on PubMed
  18. Washington SL, Baskin AS, Ameli N, Nguyen HG, Westphalen AC, Shinohara K, Carroll PR. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. AJR Am J Roentgenol. 2020 03; 214(3):574-578.  View on PubMed
  19. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019 10; 202(4):702-709.  View on PubMed
  20. Baghdanian AA, Kim YJ, Baghdanian AH, Nguyen HN, Shinohara K, Westphalen AC. Differences in negative predictive value of prostate MRI based in men with suspected or known cancer. Radiol Bras. 2019 Sep-Oct; 52(5):281-286.  View on PubMed

Go to UCSF Profiles, powered by CTSI